Tsoh 2000.

Study characteristics
Methods	Study design: secondary analysis of RCT Country: USA Data collection period: not stated Registry ID: not reported
Participants	Number of participants: N = 304; Number included in meta‐analysis: N = 304 Sample characteristics (at baseline): Age (mean): 41.0 years (SD 9.7); Sex (% male): 43.3% (132/304) Population category: general population; Specific population: general population Nicotine dependence: Fagerström Tolerance Questionnaire 5.8 (SD 2.1); Baseline cigarettes per day: 23.3 (SD 10.4); Motivation to quit: selected by motivation to quit
Interventions	Behavioural support for smoking cessation: cognitive behavioural mood management; or health education Pharmacological support for smoking cessation: nicotine gum (Trial 1); nortriptyline or placebo (Trial 2) Psychotherapeutic or psychoactive support for mental health or mood: received mood management ‐ 10 sessions of cognitive behavioural mood management intervention or 5 sessions of health education
Outcomes	Definition of cessation used: self‐reported abstinence during the last 7 days of the assessment (point‐prevalence abstinence) Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence Measure of biovalidation: expired‐air carbon monoxide of ≤ 10 ppm (both trials); urine cotinine level < 60 ng/ml (Trial 2 only) Definition of people who continued to smoke used: self‐report did not abstain during last 7 days of assessment Time point(s) at which follow‐up was conducted: end of treatment (week 12) and at 26 and 52 weeks after baseline (Trial 1); and at 24, 38 and 64 weeks after baseline (Trial 2) Outcome category: Depression Outcome measure(s): major depressive episode (MDE) diagnosed according to DSM‐III‐R criteria using ‘Inventory to Diagnose Depression’
Funding source	Supported by grants DA‐02538, DA‐23625, DA‐09253, and DA07250 from the National Institute on Drug Abuse
Author conflicts of interest	None specified
Notes	Outcome data source: Published data